Patents by Inventor Mathieu Blery

Mathieu Blery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT REGIMENS USING ANTI-NKG2A ANTIBODIES
    Publication number: 20240368281
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Application
    Filed: July 15, 2024
    Publication date: November 7, 2024
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, CAROLINE SOULAS, NICOLAÏ WAGTMANN
  • Treatment regimens using anti-NKG2A antibodies
    Patent number: 12037392
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: July 16, 2024
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Caroline Soulas, Nicolaï Wagtmann
  • Treatment of peripheral T cell lymphoma
    Patent number: 11999784
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: June 4, 2024
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet, Mathieu Blery
  • NOVEL STIM1 SPLICING VARIANTS AND USES THEREOF
    Publication number: 20240083990
    Abstract: The present invention relates to the identification of a new splice variant of STIM1 useful as a biomarker and as a target for the treatment of diseases.
    Type: Application
    Filed: January 26, 2022
    Publication date: March 14, 2024
    Inventors: OLIVIER MIGNEN, NÉLIG LE GOUX, DELPHINE BERNARD, TIFFANY BERGOT, MATHIEU BLERY
  • NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES
    Publication number: 20230303691
    Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.
    Type: Application
    Filed: June 9, 2023
    Publication date: September 28, 2023
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CAROLINE DENIS, CARINE PATUREL, NICOLAI WAGTMANN
  • NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES
    Publication number: 20230235060
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Application
    Filed: February 6, 2023
    Publication date: July 27, 2023
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, NICOLAI WAGTMANN
  • Neutralization of inhibitory pathways in lymphocytes
    Patent number: 11572410
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: February 7, 2023
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Nicolai Wagtmann
  • NKp46 BINDING AGENTS
    Publication number: 20220340661
    Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.
    Type: Application
    Filed: June 29, 2022
    Publication date: October 27, 2022
    Inventors: NADIA ANCERIZ, MATHIEU BLERY, LAURENT GAUTHIER, CARINE PATUREL
  • NKp46 binding agents
    Patent number: 11377492
    Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: July 5, 2022
    Assignee: INNATE PHARMA
    Inventors: Nadia Anceriz, Mathieu Blery, Laurent Gauthier, Carine Paturel
  • Treatment of cancers using anti-NKG2A agents
    Patent number: 11225519
    Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: January 18, 2022
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Caroline Soulas, Nicolai Wagtmann
  • TREATMENT REGIMENS USING ANTI-NKG2A ANTIBODIES
    Publication number: 20210238285
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Application
    Filed: April 8, 2021
    Publication date: August 5, 2021
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, CAROLINE SOULAS, NICOLAÏ WAGTMANN
  • NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES
    Publication number: 20210122821
    Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizaing agents and PD-1 neutralizing agents for the treatment of cancer.
    Type: Application
    Filed: December 21, 2020
    Publication date: April 29, 2021
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CAROLINE DENIS, CARINE PATUREL, NICOLAI WAGTMANN
  • Neutralization of inhibitory pathways in lymphocytes
    Patent number: 10870700
    Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: December 22, 2020
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Caroline Denis, Carine Paturel, Nicolai Wagtmann
  • NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES
    Publication number: 20200332008
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Application
    Filed: July 9, 2020
    Publication date: October 22, 2020
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, NICOLAI WAGTMANN
  • TREATMENT REGIMENS USING ANTI-NKG2A ANTIBODIES
    Publication number: 20200299383
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Application
    Filed: June 8, 2020
    Publication date: September 24, 2020
    Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, CAROLINE SOULAS, NICOLAÏ WAGTMANN
  • MICA BINDING AGENTS
    Publication number: 20200299380
    Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: February 28, 2020
    Publication date: September 24, 2020
    Inventors: Mathieu Blery, Laurent Gauthier, Ivan Perrot, Cecile Bonnafous
  • Neutralization of inhibitory pathways in lymphocytes
    Patent number: 10711063
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: July 14, 2020
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Nicolai Wagtmann
  • Treatment regimens using anti-NKG2A antibodies
    Patent number: 10676523
    Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: June 9, 2020
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Caroline Soulas, Nicolaï Wagtmann
  • Mica binding agents
    Patent number: 10577416
    Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: March 3, 2020
    Assignee: Innate Pharma, S.A.
    Inventors: Mathieu Blery, Laurent Gauthier, Ivan Perrot, Cecile Bonnafous
  • IMMUNOMODULATORY ANTIBODY DRUG CONJUGATES BINDING TO A HUMAN MICA POLYPEPTIDE
    Publication number: 20200023071
    Abstract: The present invention provides antigen-binding proteins capable of binding to human MICA polypeptides, conjugated to cytotoxic agents. Said conjugates have increased activity in the treatment of disorders characterized by MICA-expressing cells, particularly tumor cells.
    Type: Application
    Filed: February 5, 2018
    Publication date: January 23, 2020
    Inventors: MATHIEU BLERY, DELPHINE BREGEON, LAURENT GAUTHIER, FLORENCE LHOSPICE, LAURENT POUYET